Information Provided By:
Fly News Breaks for September 10, 2018
BSX
Sep 10, 2018 | 09:29 EDT
Needham analyst Mike Matson raised his price target on Boston Scientific to $43 and kept his Strong Buy rating. The analyst cites the company's latest $500M bid Augmenix, whose SpaceOAR reduces side effects associated with prostate radiotherapy. While the company expects "immaterial" earnings impact from the deal through 2019, Matson believes that it will strengthen its Urology & Pelvic Health business longer term, with added potential "revenue synergies given BSX's NxThera acquisition and legacy GreenLight XPS system".
News For BSX From the Last 2 Days
BSX
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.